A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a ...

Ascendis Health's journey from near-bankruptcy to profitability showcases how strategic leadership and financial discipline ...

Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $55,812.96 today based on a price of $151.93 for ASND at the time of writing.

Over the last 7 days, the United States market has experienced a slight decline of 1.3%, yet it has shown resilience with a 15% increase over the past year and earnings forecast to grow by 14% ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price objective lifted by stock analysts at Cantor Fitzgerald from $170.00 to $200.00 in a research note issued on Tuesday,Benzinga reports.

Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company with a $9.07 billion market capitalization focused on developing transformative therapies for rare endocrine disorders, has been ...